The global Intravitreal Injectable market was valued at US$ 13720 million in 2020 and is expected to reach US$ 21960 million by the end of 2027, growing at a CAGR of 7.1% during 2021-2027.
Intravitreal Injectable are shot of medicine into the eye. It was first used to administer drugs to treat endophthalmitis and cytomegalovirus retinitis. Recently, it is used to treat age-related macular degeneration and many other retinal diseases as well.
Global Intravitreal Injectable key players include Regeneron Pharmaceuticals (Eylea), Allergan, EyePoint Pharmaceuticals, Genentech, Kanghong Pharmaceutical, etc. Global top five manufacturers hold a share over 70%.
North Amercia is the largest market, with a share over 50%, followed by Europe and Asia-Pacific, both have a share over 40 percent.In terms of drug, Anti-VEGF is the largest segment, with a share over 85%. And in terms of disease, the largest application is Macular Edema, followed by Macular Degeneration, Retinal Vein Occlusion, etc.
Global Intravitreal Injectable Market: Drivers and Restrains
The research report has incorporated the analysis of different factors that augment the market’s growth. It constitutes trends, restraints, and drivers that transform the market in either a positive or negative manner. This section also provides the scope of different segments and applications that can potentially influence the market in the future. The detailed information is based on current trends and historic milestones. This section also provides an analysis of the volume of production about the global market and about each type from 2016 to 2027. This section mentions the volume of production by region from 2016 to 2027. Pricing analysis is included in the report according to each type from the year 2016 to 2027, manufacturer from 2016 to 2021, region from 2016 to 2021, and global price from 2016 to 2027.
A thorough evaluation of the restrains included in the report portrays the contrast to drivers and gives room for strategic planning. Factors that overshadow the market growth are pivotal as they can be understood to devise different bends for getting hold of the lucrative opportunities that are present in the ever-growing market. Additionally, insights into market expert’s opinions have been taken to understand the market better.
Global Intravitreal Injectable Market: Segment Analysis
The research report includes specific segments by region (country), by manufacturers, by Type and by Application. Each type provides information about the production during the forecast period of 2016 to 2027.
Key Companies profiled in this report are Regeneron Pharmaceuticals (Eylea), Allergan, EyePoint Pharmaceuticals, Genentech, Kanghong Pharmaceutical and more in terms of market share by sales, revenue, average pricing, product type, margins, recent developments etc.
Segment by Drug
Segment by Disease
- Macular Degeneration
- Macular Edema
- Retinal Vein Occlusion
Table of Content:
1 Intravitreal Injectable Market Overview
2 Intravitreal Injectable Market Competition by Manufacturers
3 Intravitreal Injectable Retrospective Market Scenario by Region
4 Global Intravitreal Injectable Historic Market Analysis by Type
5 Global Intravitreal Injectable Historic Market Analysis by Application
6 Key Companies Profiled
7 Intravitreal Injectable Manufacturing Cost Analysis
8 Marketing Channel, Distributors and Customers
9 Intravitreal Injectable Market Dynamics
10 Global Intravitreal Injectable Market Forecast
11 Research Finding and Conclusion
12 Methodology and Data Source
Company Name: The Market Reports
Contact Person: Shirish Gupta
Peter Barzilai is a high school pitcher and college rower turned longtime World News journalist. Peter has also written for Buzz Feed and Huffington Post and many other major publications, Peter Loves everything about sports and loves to write on trending topics and he is DailyFactsNTrends member since 2017.